WO2026002184 - GENETICALLY MODIFIED NON-HUMAN ANIMAL AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2026/002184
Publication Date
02.01.2026
International Application No.
PCT/CN2025/104229
International Filing Date
27.06.2025
Title **
[English]
GENETICALLY MODIFIED NON-HUMAN ANIMAL AND USES THEREOF
[French]
ANIMAL NON HUMAIN GÉNÉTIQUEMENT MODIFIÉ ET SES UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
ZHANG, Qi
KANG, Na
ZHAO, Huizhen
YAO, Jiawei
Priority Data
PCT/CN2024/102229
28.06.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4712 | |
| EPO | Filing, Examination, Granting | 88524 | |
| Japan | Filing, Examination, Granting | 4628 | |
| South Korea | Filing, Examination, Granting | 7305 | |
| USA | Filing, Examination, Granting | 33190 |
Total:
138,359
Contact Us
Abstract[English]
Provided are genetically modified animals and cells with humanized NKC and/or Ly49 locus. In one aspect, the genetically-modified, non-human animal comprises at an endogenous NKC locus, one or more human NKC genes, and/or at an endogenous Ly49 locus, one or more human KIR genes. In some embodiments, the animal comprises an endogenous Clec1b gene. In one aspect, the animal comprises at a safe harbor locus (e.g., an endogenous Hipp11 orRosa26 gene locus), one or more human KIR genes.[French]
L'invention concerne des animaux et des cellules génétiquement modifiés ayant un locus Ly49 et/ou NKC humanisé. Selon un aspect, l'animal non humain génétiquement modifié comprend au niveau d'un locus NKC endogène, un ou plusieurs gènes NKC humains, et/ou au niveau d'un locus Ly49 endogène, un ou plusieurs gènes KIR humains. Selon certains modes de réalisation, l'animal comprend un gène Clec1b endogène. Selon un aspect, l'animal comprend au niveau d'un locus d'hébergement sûr (par exemple, un locus de gène Hipp11 ou Rosa26 endogène), un ou plusieurs gènes KIR humains.